Market Overview

Alexion Says Clinical, Statistical Improvement in 2nd Endpoints of Eculizumab Study

Share:
Related ALXN
Baird Says Alexion Pharmaceuticals Guidance Is Conservative
Earnings Scheduled For January 29, 2015
FDA grants Priority Review for Alexion's application for asfotase alfa (Seeking Alpha)

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented data from a single-arm, open-label, investigator-initiated Phase 2 study of eculizumab (Soliris^®) as an investigational therapy in 14 patients with severe, relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The study met its primary efficacy endpoint with high degrees of clinical and statistical significance. Clinically and statistically significant improvements were also observed in key secondary endpoints. Data were presented today at a Scientific Symposium Oral Session at the American Neurological Association annual meeting in Boston, Mass.^1

Posted-In: News FDA

 

Related Articles (ALXN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content